Value adjustments totaling almost 300 million euros have a negative impact on Symrise AG’s operating profit in the fourth quarter.
As the DAX-listed fragrance and flavor manufacturer announced, the impairment of 145 million euros is being made in connection with the plan to sell the terpenes business. Symrise is also writing off 150 million euros on its stake in Swedencare AB.
Symrise is currently in advanced discussions with potential interested parties about the sale of the terpenes business, the company said. Based on the offers received so far, the international accounting standard IFRS 5 will be applied, which will result in a non-cash impairment in the fourth quarter. This has a negative impact on EBIT.
Losses in the value of the stake in Swedencare led to a “significant deviation in the results expected for the 2025 financial year compared to current capital market expectations and the published forecast,” the group continued. The non-cash impairment of the investment has a negative impact on EBITDA.
Both measures would have no impact on liquidity or operational business. They are adjusted as part of the results reporting. Symrise will present its fourth quarter and full year 2025 results on March 4th.
DJG/mgo/cln
DOW JONES
Selected leverage products on Symrise
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Symrise
The leverage must be between 2 and 20
Advertising